|
Exhibit
10.4
[*] CERTAIN INFORMATION IN THIS EXHIBIT
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.
PRIME VENDOR
AGREEMENT
FOR LONG-TERM CARE
PHARMACIES
This Prime Vendor Agreement
for Long-Term Care Pharmacies (“Agreement”) is made as
of August 1, 2007 (“Effective Date”) by
AmerisourceBergen Drug Corporation, a Delaware corporation
(“ABDC”), and PharMerica Corporation, a Delaware
corporation, on behalf of itself and its wholly owned subsidiaries
(“Customer”).
A. ABDC is a national
distributor of pharmaceutical and other products, including
prescription (“Rx”) and over-the-counter
(“OTC”) pharmaceuticals, nutritional, health and beauty
care (“HBC”) and home health care (“DME”)
products (“Products”), and related services
(“Services”).
B. Customer, Kindred
Healthcare, Inc. (“Kindred”), a Delaware corporation,
AmerisourceBergen Corporation, a Delaware corporation, PharMerica,
Inc., a Delaware corporation (“PharMerica”), and
certain other parties have entered into a Master Transaction
Agreement dated as of October 25, 2006 (“Master
Transaction Agreement”), pursuant to which, as of the
Effective Time (as defined in the Master Transaction Agreement),
PharMerica and certain of its subsidiaries (“PharMerica
LTC”) and Kindred Pharmacy Services, Inc., a Delaware
corporation, and certain of its subsidiaries (“KPS”)
will be wholly owned subsidiaries of Customer, all as provided in
the Master Transaction Agreement.
C. Pursuant to the Master
Transaction Agreement, execution of this Agreement is a condition
to the consummation of the transactions contemplated
thereby.
D. Customer, through its
wholly owned subsidiaries PharMerica LTC and KPS and their
respective direct and indirect subsidiaries, owns, operates and
manages approximately 130 long term care pharmacies as of the
Effective Time (as defined in the Master Transaction Agreement)
(collectively, the “Facilities”).
E. In addition to Facilities,
Customer also manages certain acute care pharmacies for hospitals
and other parties. Acute care pharmacies are not subject to this
Agreement and will have their own, separately negotiated agreements
for the purchase of Products and Services.
F. ABDC and PharMerica, on
behalf of PharMerica LTC are parties to that certain Prime Vendor
Agreement, dated January 19, 1998, as amended; ABDC and
Broadlane, Inc. are parties to that certain Agreement for
Distribution Services, dated December 1, 2002, as amended (the
term of which expired on December 31, 2006), to which Kindred
and its subsidiaries, including KPS, are third party beneficiaries;
and ABDC and Kindred and its subsidiaries, including KPS, are
parties to that certain interim Prime Vendor Agreement, dated
December 15, 2006, and effective January 1, 2007
(collectively, “Prior Agreements”).
G. The parties intend by this
Agreement to terminate the Prior Agreements with respect to
PharMerica LTC and KPS and to set forth their obligations to each
other for an arrangement under which ABDC will provide Products and
Services to Customer following the Effective Time (as defined in
the Master Transaction Agreement)
(“Program”).
NOW THEREFORE , the
parties agree as follows:
1. PRICING AND PAYMENT
TERMS
ABDC will be the Primary
Vendor of all requirements of Customer’s Facilities for
Products. Customer will pay, within terms, Product costs and
Program fees pursuant to payment terms in Exhibit
“1” (“Pricing/Payment Terms”).
“Primary Vendor” means Customer purchases from ABDC
(including Products purchased from ABDC * that are administered by
*) no less than * of all prescription pharmaceutical Products it
purchases, as verified *, and meets * in Paragraph 5(A) of the
Pricing/Payment Terms. Notwithstanding the foregoing, Customer
may
1
purchase directly from a manufacturer
if, due to a product shortage or allocation, the manufacturer
requires that Customer do so. In accordance with Section 4 of
this Agreement, the foregoing * will not apply to * with existing
agreements with other distributors. Orders for Products will be
electronically transmitted (including Schedule II controlled
substances when allowed) and will describe Products that ABDC will
provide to Customer, the quantity and designated delivery location.
Other than supplier back-ordered Products, ABDC will make
reasonable efforts to deliver orders placed by ABDC’s normal
order cut-off time by the next delivery day. All payment plans must
be by electronic funds transfer (EFT). The * in the Pricing/Payment
Terms, terms, and conditions under this Agreement * must be *
contracting with ABDC as of the date hereof. A * is a third-party
pharmacy customer with * purchase volume and *, taking into
consideration *.
2. PRxO GENERICS PURCHASE
PROGRAM
Customer must participate in
the generic formulary purchase program (“PRxO Generics
Purchase Program”) as provided in this Agreement and pursuant
to standard PRxO Generics program requirements as amended from time
to time by ABDC. The PRxO Generics Purchase Program is a * which
provides Customer *. Customer is able to benefit by having ABDC
administer the PRxO Generics Purchase Program for a *, as specified
in Paragraph 2 of the Pricing/Payment Terms. Accordingly, Customer
will purchase from ABDC * of its generic pharmaceutical purchases,
including the “Top 100” generic pharmaceutical
Products; provided, however, that Customer may purchase any generic
pharmaceuticals (including, without limitation, injectables or
Products in unit-dose packages that are not available under the
PRxO Generics Purchase Program) from a source other than ABDC,
without impact to the requirements under this Agreement if such
Products are not available under the PRxO Generics Purchase
Program. The Top 100 is a list determined from time to time by ABDC
of more than one hundred commonly used generic pharmaceutical
Products. Customer authorizes ABDC as its sole agent to develop and
implement a generic pharmaceutical Product list for the Term. With
respect to each Product purchased by Customer under the PRxO
Generics Purchase Program, ABDC shall use its * to provide Customer
* prior to changing suppliers of such Products. Customer will
purchase from ABDC each * no less than the * of generic
pharmaceutical Products as set forth in paragraph 5(A) of the
Pricing/Payment Terms. Any changes by ABDC in its PRxO Generics
Program or in the Top 100 list as applicable to Customer will be
non-discriminatory, generally applicable to ABDC’s customers
and consistent with the terms of this Agreement.
3. SPECIALTY DISTRIBUTIONS AND
*
ABDC will provide to Customer
* that are in * due to, for example, manufacturer shortages or
unanticipated demand, including any specialty Products or other
Products with limited distribution or supply. ABDC makes such
allocations based upon *. Upon request, ABDC will attempt to
acquire short-supply Products and, upon their purchase by Customer,
such inventory would be * and would not *. Additionally, upon
request, ABDC can order short-supply Products, which Products can
be “shipped upon arrival” to Customer’s
Facilities.
4. CUSTOMER LOCATIONS &
DELIVERIES
ABDC will deliver Products to
each Facility five days a week (Monday – Friday), once a day
except holidays and warehouse physical inventory days. ABDC will
provide * at its distribution centers * hours a day, * days a week,
for which ABDC will provide Customer with emergency contact
information for after-hours access. Additionally, Customer will be
entitled to *.
[*] CERTAIN INFORMATION ON THIS PAGE HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED
PORTIONS.
2
* delivery per * at *. Customer will be
charged * for each additional emergency order delivered to the
Facility. Customer may receive * emergency will-call order per
Facility * (as long as it is picked up by Customer from
ABDC’s distribution center during hours such distribution
center is staffed) *. ABDC will use * to meet a requested delivery
time for emergency orders. If ABDC cannot do so, Customer may fill
emergency orders outside the Program on such occasions using
another provider notwithstanding * in this Agreement. A newly
acquired Facility shall become a Facility under this Agreement upon
acquisition of such facility by Customer, provided that any newly
acquired facility with an existing agreement with another
distributor will become a Facility under this Agreement upon the
earlier of expiration of such existing agreement or the date
Customer may terminate such agreement according to its terms, with
or without cause, without breaching it or *. Service to Facilities
in Alaska, Hawaii and U.S. territories may be subject to a delivery
surcharge.
5. RETURNED GOODS
POLICY
Customer will only return
Products to ABDC in accordance with ABDC’s enhanced policy
for return Products, a copy of which is attached as Exhibit
4 (“Returns Policy”). If Customer returns more than
* of its OTC Net Purchases, or * of its pharmaceutical Net
Purchases in any month, Customer may be assessed an additional
restocking fee over any standard stocking fee in the Returns
Policy. Customer will return only Product purchased from ABDC for
which Customer has submitted the invoice number and date of
purchase. ABDC may reject returns not accompanied by the invoice
number and date of purchase or that exceed in amount either the *
return limit or the amount on the referenced invoice number. ABDC
reserves the right to refuse all future returns from Customer in
the event that Customer submits any counterfeit Product for return.
The calculation of Customer returns, Customer OTC Net Purchases,
and all other calculations under this Agreement related to the
volume of Customer’s purchases of Products will be based on
*.
6. ADDITIONAL SERVICES &
PROVISIONS
A. Services are listed in
Exhibit “2” . Terms, conditions and other
provisions are set forth in Exhibit “3”
(“Provisions”).
B. ABDC may, from time to
time, develop policies and procedures relative to new or existing
Services offered to customers, on an interim or as-needed basis. If
ABDC develops such policies or procedures or changes current ones,
ABDC will notify Customer in writing at least thirty (30) days
before such changes are effective. Any changes by ABDC that apply
to Customer from time to time under this Agreement, including its
exhibits, must be non-discriminatory, generally applicable to
ABDC’s customers, and consistent with the terms of this
Agreement.
7. TERM OF AGREEMENT
A. The parties intend by this
Agreement to replace and terminate the Prior Agreements as of the
Effective Date. Except as otherwise agreed, rights and obligations
of the parties under each Prior Agreement that accrued with respect
to PharMerica or KPS prior to the Effective Date will survive and
be satisfied by Customer according to terms of each Prior
Agreement.
B. Subject to termination of
this Agreement pursuant to Paragraph 5 of the Provisions, the Term
will be from the Effective Date until July 31, 2012. Unless
either party provides notice of termination at least 90 days prior
to the expiration of the Term, this Agreement will continue on a
month-to-month basis upon expiration of the Term (“Extended
Term”), subject to termination pursuant to Paragraph 5 of the
Provisions.
8. RECORDS
To the extent required by 42
U.S.C. §1395x(v)(1), until four (4) years after
termination of this Agreement, ABDC will make available upon
written request to the Secretary of the U.S. Department of
Health & Human Services, the Comptroller General, or their
authorized representatives, a copy of this Agreement and
[*] CERTAIN INFORMATION ON THIS PAGE HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED
PORTIONS.
3
all records required to certify the
nature and extent of costs of Products and Services provided by
ABDC under this Agreement. ABDC will ensure, to the extent it
carries out its duties through a subcontract with a value or cost
of $10,000 or more in a twelve (12) month period with a
related organization, such subcontract will contain similar
provisions. Notwithstanding the foregoing, ABDC will have no
obligation to make public documents subject to attorney-client
privilege.
9. NOTICES
Notices must be in writing
and sent certified mail, prepaid, return receipt requested, or sent
by facsimile to the address or facsimile number below. Parties may
change this information by written notice to the other party.
Pursuant to the Telephone Consumer Protection Act of 1991, 47
U.S.C. §227, Customer consents to receiving notices, including
product updates, recalls, new product launches and programs,
advertisements and other marketing materials by telephone facsimile
(“fax”) machine from ABDC, its affiliates and their
related companies, to the fax number set forth below.
|
|
|
| To
Customer: |
|
PharMerica Corporation
1901 Campus Place
Louisville, KY 40299
Attn: Chief Financial Officer
CC: General Counsel
Fax: (502) 261-2375
|
|
|
| with a copy to: |
|
Holland & Knight LLP
10 St. James Avenue, 11th
Floor
Boston, MA 02116
Attn: Jeffrey W. Mittleman,
Esq.
Fax: (617) 523-6850
|
|
|
| To
ABDC: |
|
AmerisourceBergen Drug
Corporation
1300 Morris Drive
Chesterbrook, PA 19087-5594
Attn: Senior Vice President, Health
Systems
Fax: 610-727-3601
|
|
|
| with a copy
to: |
|
AmerisourceBergen Corporation
1300 Morris Drive
Chesterbrook, Pennsylvania
19087-5594
Attn: General Counsel
Fax: (610) 727-3612
|
10. EXHIBITS
The following exhibits to
this Agreement are incorporated by this reference.
[*] CERTAIN INFORMATION ON THIS PAGE HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED
PORTIONS.
4
IN WITNESS WHEREOF, the
parties have had a duly authorized officer, partner or principal
execute this Prime Vendor Agreement as of the Effective
Date.
|
|
|
|
|
|
|
|
|
|
CUSTOMER:
PharMerica Corporation
|
|
|
|
ABDC:
AmerisourceBergen Drug
Corporation
|
|
|
|
|
|
| By: |
|
/s/ Gregory S.
Weishar
|
|
|
|
By: |
|
/s/ Terrance P.
Haas
|
| Name: |
|
Gregory S.
Weishar |
|
|
|
Name: |
|
Terrance P.
Haas |
| Title: |
|
CEO |
|
|
|
Title: |
|
President |
[*] CERTAIN INFORMATION ON THIS PAGE HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED
PORTIONS.
EXHIBIT 1
TO
PRIME VENDOR
AGREEMENT
PRICING / PAYMENT
TERMS
In addition to payment for Products,
Customer will pay ABDC the following Program and other fees for
ABDC’s Product distribution and Services for Customer and its
Facilities. Except as otherwise provided, payments are due within *
days from ABDC’s invoice date. Pricing does not reflect any
administrative or other fee to a group purchasing organization or
buying group (“GPO”). If Customer contracts with a GPO,
Customer will pay any such fees to the applicable GPO (or any
increase in such fees) during the Term. In any event, ABDC will not
pay a GPO fee unless and until a group designation form signed by
Customer is filed with ABDC.
1. PROGRAM FEES
A. Price of Goods .
Customer will pay the following Price of Goods based upon the
definition of “Cost” below for Products other than
Products and Services designated as ABDC Special Price Products.
ABDC will add to the billed amount any applicable sales, use,
business and occupation, gross receipts or other tax. Price of
Goods shall be fixed * for the * quarters of the Term. Thereafter,
Price of Goods may be adjusted in accordance with the following
matrix at the beginning of the sixth calendar quarter of the Term
and each quarter thereafter based upon Customer’s actual
total net purchase volume over the immediately prior
quarter.
|
|
|
|
|
|
|
| |
|
Total Quarterly Rx Product
Volume
|
|
Branded Rx Price of Goods* |
|
Tier
|
|
|
|
Weekly
Payment |
|
|
|
1
|
|
* up to *
|
|
* |
|
|
|
2
|
|
* up to *
|
|
* |
|
|
|
3
|
|
* up to *
|
|
* |
|
|
|
4
|
|
* & *
|
|
* |
|
|
Selected Products *.
[*] CERTAIN INFORMATION ON THIS PAGE HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED
PORTIONS.
6
B. Additional *
Services . The additional * Services in Exhibit
“2” will be provided to Customer’s
Facilities, at the election of Customer’s Facilities, by ABDC
* if Customer maintains ABDC as its Primary Vendor. In the event
Customer does not maintain ABDC as its Primary Vendor, such
Services will be provided *.
C. Contract
Administration . In administering Customer’s supplier
contracts, including those established by Customer on its own or
those established by a GPO under which Customer participates,
Customer must (i) provide a copy of new contracts,
(ii) comply with supplier’s terms, (iii) use all
products for its “own use” (as defined in judicial and
legislative interpretations), (iv) notify ABDC at least * days
before it changes suppliers, and (v) upon changing suppliers,
assist ABDC in disposing of any excess inventory acquired for
Customer. Additionally, Customer will notify ABDC before
discontinuing purchases of any special inventory that it has
requested that ABDC stock (whether or not pursuant to a contract)
and assist ABDC in disposing of any excess of such inventory.
Promptly after receiving notice of the denial of, or failure to
pay, GPO or manufacturer/supplier chargebacks, ABDC shall provide
Customer written notice of any unpaid chargebacks, and when
invoiced, Customer will promptly reimburse ABDC for any unpaid
chargebacks that are (x) denied by a GPO or
manufacturer/supplier or (y) not paid within * days and, in
either case, Customer will look solely to such GPO or
manufacturer/supplier for redress; provided that the unpaid
chargeback is processed through ABDC’s standard credit and
rebill procedures.
2. PRxO GENERICS PURCHASE
PROGRAM
A. Administration
Services . ABDC will have full responsibility for administering
the PRxO Generics Purchase Program, including supplier selection,
Product selection, Product price negotiation, contract
administration, purchasing, automated compliance assurance,
contract management and reporting. Under the PRxO Generics Purchase
Program, ABDC will invoice Customer at * under *, * to Customer, *
to ABDC’s * .
B. * . ABDC will
provide such PRxO Generics Purchase Program services for * of the
Contrac
|